Atara Biotherapeutics Weighs Strategic Options After MS Treatment Fails to Meet Primary Endpoint
By Ben Glickman
Atara Biotherapeutics is evaluating strategic options for its progressive multiple sclerosis treatment after a trial of the therapy didn’t meet its primary endpoint.
The Thousand Oaks, Calif.-based immunotherapy company said that ATA188’s Phase 2 trial for use in treating non-active PMS had not reached its primary endpoint of confirmed disability improvement after 12 months.
Atara will “significantly reduce” spending on the ATA188 program and focus resources on its other pipelines.
The company said it is reviewing all of the data from the trial, including lower disability improvement than in prior studies and a larger than expected placebo effect.
Atara now expects its cash runway to extend beyond the third quarter of 2025.
Write to Ben Glickman at [email protected]
Read the full article here